Zhu Cuizhen, Bi Ran, Hu Yuliang, Zhou Hui, Zhu Daomin, Isaacson Brian, Li Qingwei, Lin Yezhe
Department of Sleeping Disorder, Anhui Mental Health Center, Hefei, Anhui, China.
Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gen Psychiatr. 2020 Mar 11;33(2):e100112. doi: 10.1136/gpsych-2019-100112. eCollection 2020.
Restless legs syndrome (RLS) is a common sleep-related movement disorder characterised by an uncomfortable urge to move the legs that occurs during periods of inactivity. Although there have been many case reports on antipsychotic-induced RLS, ziprasidone has never been reported as a cause of RLS. We present a case of a female patient with schizophrenia who presented with symptoms of RLS following the administration of high doses of ziprasidone added to quetiapine and valproate. The patient's symptoms of RLS occurred following the administration and titration of ziprasidone to 160 mg, and were relieved upon reducing the dose to 120 mg/day. Other potential causative medications and differential diagnoses that could have caused similar symptoms were excluded. Clinicians should be aware of the potential for ziprasidone-induced RLS. Dopamine and serotonin interaction could be the mechanism underlying ziprasidone-induced RLS.
不宁腿综合征（RLS）是一种常见的与睡眠相关的运动障碍，其特征是在不活动期间出现腿部不适的活动冲动。尽管有许多关于抗精神病药物诱发RLS的病例报告，但齐拉西酮从未被报道为RLS的病因。我们报告一例患有精神分裂症的女性患者，在喹硫平和丙戊酸盐基础上加用高剂量齐拉西酮后出现RLS症状。该患者的RLS症状在齐拉西酮给药并滴定至160mg后出现，将剂量减至120mg/天后症状缓解。排除了其他可能导致类似症状的潜在致病药物和鉴别诊断。临床医生应意识到齐拉西酮诱发RLS的可能性。多巴胺和5-羟色胺相互作用可能是齐拉西酮诱发RLS的潜在机制。
